These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 25544686)
41. Drug-induced phospholipidosis: are there functional consequences? Reasor MJ; Kacew S Exp Biol Med (Maywood); 2001 Oct; 226(9):825-30. PubMed ID: 11568304 [TBL] [Abstract][Full Text] [Related]
42. Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. Vitovic P; Alakoskela JM; Kinnunen PK J Med Chem; 2008 Mar; 51(6):1842-8. PubMed ID: 18318464 [TBL] [Abstract][Full Text] [Related]
43. Modeling phospholipidosis induction: reliability and warnings. Goracci L; Ceccarelli M; Bonelli D; Cruciani G J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521 [TBL] [Abstract][Full Text] [Related]
44. Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells. Scuntaro I; Kientsch U; Wiesmann UN; Honegger UE Br J Pharmacol; 1996 Nov; 119(5):829-34. PubMed ID: 8922728 [TBL] [Abstract][Full Text] [Related]
45. In vitro validation of drug-induced phospholipidosis. Park S; Choi YJ; Lee BH J Toxicol Sci; 2012; 37(2):261-7. PubMed ID: 22467016 [TBL] [Abstract][Full Text] [Related]
46. In vitro assays and biomarkers for drug-induced phospholipidosis. Monteith DK; Morgan RE; Halstead B Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389 [TBL] [Abstract][Full Text] [Related]
47. Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. Thompson KL; Zhang J; Stewart S; Rosenzweig BA; Shea K; Mans D; Colatsky T Toxicol Lett; 2012 Sep; 213(2):285-91. PubMed ID: 22828012 [TBL] [Abstract][Full Text] [Related]
48. Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development. Loryan I; Hoppe E; Hansen K; Held F; Kless A; Linz K; Marossek V; Nolte B; Ratcliffe P; Saunders D; Terlinden R; Wegert A; Welbers A; Will O; Hammarlund-Udenaes M Mol Pharm; 2017 Dec; 14(12):4362-4373. PubMed ID: 29099189 [TBL] [Abstract][Full Text] [Related]
49. Fluorescent high-content imaging allows the discrimination and quantitation of E-LDL-induced lipid droplets and Ox-LDL-generated phospholipidosis in human macrophages. Grandl M; Schmitz G Cytometry A; 2010 Mar; 77(3):231-42. PubMed ID: 20014301 [TBL] [Abstract][Full Text] [Related]
50. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623 [TBL] [Abstract][Full Text] [Related]
51. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals. Jiang Z; Reilly J J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505 [TBL] [Abstract][Full Text] [Related]
52. A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. Buratta S; Urbanelli L; Ferrara G; Sagini K; Goracci L; Emiliani C Biochem Pharmacol; 2015 Jun; 95(3):201-9. PubMed ID: 25881747 [TBL] [Abstract][Full Text] [Related]
53. Raman and fluorescence imaging of phospholipidosis induced by cationic amphiphilic drugs in endothelial cells. Bik E; Orleanska J; Mateuszuk L; Baranska M; Majzner K; Chlopicki S Biochim Biophys Acta Mol Cell Res; 2022 Mar; 1869(3):119186. PubMed ID: 34902479 [TBL] [Abstract][Full Text] [Related]
54. Adaptation of an in vitro phospholipidosis assay to an automated image analysis system. Schurdak ME; Vernetti LA; Abel SJ; Thiffault C Toxicol Mech Methods; 2007; 17(2):77-86. PubMed ID: 20020975 [TBL] [Abstract][Full Text] [Related]
55. Increased levels of urinary phenylacetylglycine associated with mitochondrial toxicity in a model of drug-induced phospholipidosis. Doessegger L; Schmitt G; Lenz B; Fischer H; Schlotterbeck G; Atzpodien EA; Senn H; Suter L; Csato M; Evers S; Singer T Ther Adv Drug Saf; 2013 Jun; 4(3):101-14. PubMed ID: 25083254 [TBL] [Abstract][Full Text] [Related]
56. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096 [TBL] [Abstract][Full Text] [Related]
57. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells. Pospischil A; Walther P; Dingemanse J Exp Toxicol Pathol; 2010 Sep; 62(5):567-71. PubMed ID: 19674876 [TBL] [Abstract][Full Text] [Related]
58. Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Gunesch AP; Zapatero-Belinchón FJ; Pinkert L; Steinmann E; Manns MP; Schneider G; Pietschmann T; Brönstrup M; von Hahn T Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513799 [TBL] [Abstract][Full Text] [Related]
59. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956 [TBL] [Abstract][Full Text] [Related]
60. Identification of integrative hepatotoxicity induced by lysosomal phospholipase A2 inhibition of cationic amphiphilic drugs via metabolomics. Oh HA; Kim YJ; Moon KS; Seo JW; Jung BH; Woo DH Biochem Biophys Res Commun; 2022 Jun; 607():1-8. PubMed ID: 35358871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]